On August 27, 2024 Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, reported that it will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial at the Society of Hematologic Oncology (SOHO) Annual Meeting taking place September 4-7, in Houston, Texas (Press release, Syros Pharmaceuticals, AUG 27, 2024, View Source [SID1234646123]). Additionally, Syros announced that company management will participate in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11 in New York City.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details are as follows:
12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024)
Presentation Title: SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
Session Date & Time: Wednesday, September 4, 2024, 5:15-6:30 PM CT (6:15-7:30 PM ET)
Location: George R. Brown Convention Center
Poster Number: AML-347
The poster will be available on the Publications and Abstracts section of the Syros website at www.syros.com following the session.
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Date & Time: Monday, September 9, 2024, 11:30 AM ET
Location: Lotte New York Palace
A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.